Top Markets
#1 B3 (Base) B3 (Base) +14.17%
#2 Janction Janction +12.47%
#3 DMT-NAT DMT-NAT +11.90%
#4 Fake World Assets Fake World Assets +11.22%
#5 TENDIES TENDIES +6.21%
#6 Status Status +4.85%
#7 GoPlus Security GoPlus Security +4.76%
#8 龙虾 (Lobster) 龙虾 (Lobster) +4.30%
#9 Provenance Blockchain Provenance Blockchain +3.88%
#10 Everything Everything +3.72%
Coin of the day
B3 (Base) B3 (Base)
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
Classificação em ações #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Preço da ação
$0.6379482
Última sincronização: 2023-05-22
Valor de mercado
$5.98M
Variação (1 dia)
-0.44%
Variação (1 ano)
0.00%
País
FR
Negociar Nicox S.A. (COX)

Categoria

Healthcare
Lucros da Nicox S.A. (COX)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Nicox S.A., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Nicox S.A. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE